Hematopoietic stem-cell transplantation from an unrelated donor.
When an HLA-matched sibling is not available and nontransplant approaches have been ineffective, transplantation of hematopoietic stem cells from an unrelated donor can effect a cure in some patients with chronic myelogenous leukemia. Even when successful, however, transplantation is a rigorous and prolonged process whose complications include infection and graft-versus-host disease. Improvements in hematopoietic stem-cell transplantation as well as innovative nontransplant approaches may improve the outcome in these patients.
McGlave
P
P
Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School-Minneapolis, USA.
D000328:Adult; D000465:Algorithms; D001856:Bone Marrow Examination; D003663:Decision Trees; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods* / Q000639:trends; D006650:Histocompatibility Testing; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D007958:Leukocyte Count; D008297:Male; D010353:Patient Education as Topic; D018579:Patient Selection; D010677:Philadelphia Chromosome; D014184:Transplantation, Homologous / Q000009:adverse effects* / Q000379:methods* / Q000639:trends; D016896:Treatment Outcome
D016898:Interferon-alpha